What is the typical dose for a heparin (unfractionated heparin) bolus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Heparin Bolus Dosing

For acute myocardial infarction (MI), administer an initial intravenous bolus of 60 U/kg (maximum 4,000-5,000 units) followed by a continuous infusion of 12 U/kg/hour, targeting an aPTT of 50-70 seconds. 1

Context-Specific Dosing Recommendations

ST-Elevation Myocardial Infarction (STEMI)

Primary PCI without GP IIb/IIIa inhibitors:

  • Initial bolus: 100 U/kg (or 70-100 U/kg weight-adjusted) 2
  • Target ACT: 250-350 seconds 2
  • Additional boluses may be given to maintain therapeutic ACT 2

Primary PCI with GP IIb/IIIa inhibitors:

  • Initial bolus: 60 U/kg 2
  • Target ACT: 200-250 seconds 2
  • Lower dosing reduces bleeding risk when combined with platelet inhibitors 2, 3

With fibrinolytic therapy (alteplase):

  • Initial bolus: 60 U/kg (maximum 4,000 units) 1
  • Followed by 12 U/kg/hour infusion (maximum 1,000 U/hour) 1
  • Target aPTT: 50-70 seconds 1

Non-ST-Elevation MI and Unstable Angina

  • Initial bolus: 60-70 U/kg (maximum 5,000 units) 1
  • Followed by 12-15 U/kg/hour continuous infusion 1
  • Target aPTT: 50-70 seconds (1.5-2.5 times control) 2, 1

Venous Thromboembolism (for comparison)

  • Initial bolus: 80 U/kg 2, 4, 5
  • Followed by 18 U/kg/hour infusion 2, 4, 5
  • Target aPTT: 1.5-2.5 times control (typically 45-75 seconds) 4

Critical Timing Considerations

Achieving therapeutic anticoagulation rapidly is essential:

  • Patients who reach therapeutic aPTT within 24 hours have significantly lower mortality rates in pulmonary embolism 2, 4
  • Weight-based dosing achieves therapeutic levels faster than fixed-dose regimens (97% vs 77% within 24 hours) 5
  • Subtherapeutic anticoagulation in the first 24 hours increases recurrent thromboembolism risk to 25% 6

Monitoring Protocol

Initial monitoring:

  • First aPTT check: 4-6 hours after bolus for continuous infusion 7
  • First aPTT check: 3 hours after bolus for VTE treatment 2
  • ACT monitoring during PCI: maintain target throughout procedure 2

Ongoing monitoring:

  • aPTT every 6 hours until therapeutic, then daily 7, 5
  • Platelet counts periodically throughout therapy 7
  • Hematocrit and occult blood in stool 7

Common Pitfalls to Avoid

Fixed-dose regimens are inferior:

  • Standard 5,000-unit bolus followed by 1,000 U/hour results in higher recurrent thromboembolism rates (relative risk 5.0) 5
  • Weight-based dosing is superior and should always be used when patient weight is available 2, 5

Excessive anticoagulation with combination therapy:

  • When combining heparin with GP IIb/IIIa inhibitors, reduce bolus to 60 U/kg to avoid bleeding complications 2, 3
  • Bleeding rates increase from 3.9% to 16.4% with conventional higher dosing 3

Inadequate initial dosing:

  • Failure to achieve therapeutic anticoagulation within 24 hours dramatically increases adverse outcomes 2, 4
  • Do not use enteric-coated aspirin concurrently due to slow onset 2

Special Populations

Pediatric patients (cardiac catheterization):

  • Initial bolus: 100-150 U/kg 2
  • Target ACT: >200 seconds (250-300 seconds for high-risk procedures) 2
  • A 50 U/kg bolus is insufficient and not recommended 2

Cardiovascular surgery:

  • Initial dose: minimum 150 U/kg 7
  • 300 U/kg for procedures <60 minutes 7
  • 400 U/kg for procedures >60 minutes 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Heparin dosing in patients undergoing coronary intervention.

The American journal of cardiology, 1998

Guideline

Heparin Dosing for Venous Thromboembolism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.